Castle Biosciences (CSTL) reported $344M in revenue for fiscal 2025, +3.7% year on year. That ranks #2417 by revenue among 2853 SEC filers and #240 in Healthcare. It posted a net loss of −$24.2M for the same year. Revenue has grown 47.4% a year on average since 2018 ($22.8M then). The fiscal 2025 balance sheet shows $579M in total assets, $117M in cash and $9.6M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $344M | +3.7% | FY20252025-12-31 |
| Gross profitGrossProfit | $53.0M | +18.9% | FY20202020-12-31 |
| Operating incomeOperatingIncomeLoss | −$42.8M | −$51.5M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$24.2M | −$42.4M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $64.3M | −0.8% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $36.0M | +27.2% | FY20252025-12-31 |
| Total assetsAssets | $579M | +8.9% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $471M | +3.3% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $117M | −2.5% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $9.6M | −1.1% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $83.7M | −$14.5M | Open → |
| Q2 20262026-06-30 | $104M | −$2.1M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Castle Biosciences Inc
- Ticker
- CSTL
- Exchange
- Nasdaq
- SIC classification
- Services-Medical Laboratories (8071)
- Fiscal year end
- 12-31
- CIK
- 0001447362
Filings
- 10-QJul 30, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| InmodeINMD | $370M | $93.8M |
| MannkindMNKD | $349M | $5.9M |
| InogenINGN | $349M | $22.7M |
| Castle BiosciencesCSTL | $344M | −$24.2M |
| Tactile Systems TechnologyTCMD | $330M | $19.1M |
| Fulgent GeneticsFLGT | $323M | −$60.5M |
| DocgoDCGO | $322M | −$196M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Castle Biosciences — Key figures |url=https://companiesranked.com/en/company/castle-biosciences |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Castle Biosciences — Key figures. CompaniesRanked. https://companiesranked.com/en/company/castle-biosciencesBibTeX
@misc{companiesranked-en-company-castle-biosciences-2026,
author = {{CompaniesRanked}},
title = {{Castle Biosciences — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/castle-biosciences}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-012272 · February 26, 2026
{{cite web |title=Castle Biosciences — Key figures — 10-K (0001628280-26-012272) |url=https://www.sec.gov/Archives/edgar/data/1447362/000162828026012272/cstl-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.